Page last updated: 2024-11-04

succinylacetone and HbS Disease

succinylacetone has been researched along with HbS Disease in 1 studies

succinylacetone: inhibitor of heme biosynthesis
4,6-dioxoheptanoic acid : A dioxo monocarboxylic acid that is heptanoic acid in which oxo groups replace the hydrogens at positions 4 and 6. It is an abnormal metabolite of the tyrosine metabolic pathway and a marker for type 1 tyrosinaemia.

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fibach, E	1
Kollia, P	1
Schechter, AN	1
Noguchi, CT	1
Rodgers, GP	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
A Phase 2, Open-Label, Multiple-Dose Study Investigating the Efficacy and Safety of Panhematin in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome[NCT00467610]			Phase 2	6 participants (Actual)	Interventional	2007-05-31	Terminated (stopped due to lack of efficacy.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Hematological Improvement Rate at Week 8 as Defined by the IWG 2000 Criteria for Response Assessment, 2000 Version

(NCT00467610)
Timeframe: At 8 weeks from start of therapy

Intervention	participants (Number)
Group 1	1

Number of Patients Demonstrating Hematological Improvement to Panhematin® at Week 4.

"Hematological improvement (HI)~Major:~HI-Erythroid:>2 g/dL rise in hemoglobin, or transfusion independence HI-Neutrophil: Absolute increase of >500/mm3, or >100% increase HI-Platelet: Absolute increase of >30,000, or transfusion independence~Minor:~HI-Erythroid:1 to 2 g/dL increase in hemoglobin or 50% decrease in transfusion dependence.~HI-P: For patients with pretreatment platelet count < 100,000/mm3, ≥ 50% increase with a net increase > 10,000/mm3 but < 30,000/mm3.~HI-N: For patients with pretreatment ANC < 1500/mm3, ≥ 100% increase, but < 500/mm3 increase." (NCT00467610)
Timeframe: 4 weeks after initiation of treatment with Panhematin

Intervention	participants (Number)
Group 1	0

Response Rate ( CR+PR) at Week 8, Based on the IWG Criteria for Response Assessment ( 2000 Version)

"Complete response(CR): <5% blasts in the bone marrow,with normal maturation of all cell lines, Hemoglobin >11 g/dL, neutrophils>1500/mm3 platelets>100,000/mm3.~Partial response (PR): >50% decrease in blasts, or less advanced IPSS than pretreatment value, same hematological parameters as in CR.~Stable disease (SD): No evidence of disease progression in bone marrow, stable peripheral blood counts failure: Increase in bone marrow blast percentage, progression to more advanced IPSS than pretreatment and worsening of cytopenias.~(Cheson, 2000)" (NCT00467610)
Timeframe: After 8 weeks of therapy with panhematin

Intervention	Participants (Number)
Group 1	0

Safety and Tolerability of Panhematin®.

Number of patients with no adverse events. (NCT00467610)
Timeframe: participants were followed during therapy with panhematin, and up to six months post completion of therapy, average of 8 months.

Intervention	participants (Number)
Group 1	6

Other Studies

1 other study available for succinylacetone and HbS Disease

Article	Year
Hemin-induced acceleration of hemoglobin production in immature cultured erythroid cells: preferential enhancement of fetal hemoglobin. Blood, 1995, May-15, Volume: 85, Issue:10 Topics: Anemia, Sickle Cell; beta-Thalassemia; Cell Division; Cells, Cultured; Drug Synergism; Erythroid Pre	1995